Eisai said its Alzheimer’s disease drug Leqembi will go on sale in Japan on 20 December after being included in the national health insurance price list. Intravenous treatment with the drug, developed with U.S. partner Biogen, will cost about 2.98 million yen (US$20,438) per patient per year, according to a Japanese health ministry panel ruling the same day.